Olema Oncology to Present at Two Upcoming Investor Conferences
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on women's cancers, announced participation in two investor conferences this November.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on women's cancers, announced participation in two investor conferences this November. The events include the Jefferies London Healthcare Conference on November 16, 2021, at 5:00 p.m. GMT, and the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, at 11:45 a.m. ET. Live webcasts will be available on Olema’s website and archived for 14 days. Olema’s lead product, OP-1250, targets ER-positive breast cancer and is currently undergoing clinical trials.
Details
News Market Reaction – OLMA
The recorded move for OLMA in the trading session of this news was -2.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that management will participate in two upcoming investor conferences in November.
Details for the company’s participation are as follows:
- Event: Jefferies London Healthcare Conference
Date: Tuesday, November 16, 2021
Time: 5:00 p.m. GMT (12:00 p.m. ET / 9:00 a.m. PT)
Format: Live Fireside Chat - Event: 4th Annual Evercore ISI HealthCONx Conference
Date: Tuesday, November 30, 2021
Time: 11:45 a.m. ET (8:45 a.m. PT)
Format: Live Fireside Chat
Live webcasts of these presentations may be accessed under the Investors & Media section of Olema’s website (www.olema.com) and will be archived for 14 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is based in San Francisco and has operations in Cambridge, Massachusetts.
Contact:
Eva Stroynowski
Vice President, Communications and Investor Relations
eva@olema.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.